General Information of Drug (ID: DMD1S92)

Drug Name
Pyrrolo-pyrazine derivative 4 Drug Info
Synonyms PMID27774822-Compound-Figure7ExampleI-4
Cross-matching ID
TTD Drug ID
DMD1S92

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Janus kinase 3 (JAK-3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tofacitinib DMBS370 Rheumatoid arthritis FA20 Approved [2]
Ritlecitinib DMYKNME Alopecia areata ED70.2 Approved [3]
ASP-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [4]
VX-509 DM2U3MX Rheumatoid arthritis FA20 Phase 2/3 [5]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [3]
ATI-501 DMTY6OF Alopecia ED70 Phase 2 [6]
ATI-502 DM8NODR Alopecia ED70 Phase 2 [7]
TD-8236 DMTOMJN Asthma CA23 Phase 2 [8]
ALXN2075 DM1BSD8 Non-hodgkin lymphoma 2B33.5 Phase 1/2 [9]
SNA-125 DM8L1GJ Atopic dermatitis EA80 Phase 1 [3]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fostamatinib DM6AUHV Immune thrombocytopenic purpura 3B64.13 Approved [10]
Fostamatinib disodium DM3274D Thrombocytopenia 3B64 Phase 3 [11]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [12]
TAK-659 DMJH3U0 Diffuse large B-cell lymphoma 2A81 Phase 2 [13]
GS-9876 DM9Q2B6 Cutaneous lupus erythematosus EB5Z Phase 2 [14]
GS-9973 DMKWCTR Acute myeloid leukaemia 2A60 Phase 2 [15]
Cevidoplenib DM9QU5G Rheumatoid arthritis FA20 Phase 2 [16]
HM43239 DMV1SDA Acute myeloid leukaemia 2A60 Phase 1/2 [17]
ALXN2075 DM1BSD8 Non-hodgkin lymphoma 2B33.5 Phase 1/2 [9]
SKI-O-703 DMTSKXR Rheumatoid arthritis FA20 Phase 1 [14]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Janus kinase 3 (JAK-3) TTT7PJU JAK3_HUMAN Inhibitor [1]
Tyrosine-protein kinase SYK (SYK) TTOU65C KSYK_HUMAN Inhibitor [1]

References

1 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
5 Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
6 Clinical pipeline report, company report or official report of Aclaris Therapeutics.
7 ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
8 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
9 The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 Company report (Portola Pharmaceuticals)
13 J Clin Oncol 32:5s, 2014 (suppl; abstr 8580).
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15 An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43.
16 A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models. Clin Exp Immunol. 2023 Mar 8;211(1):31-45.
17 Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.